UBS Group AG decreased its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 79.2% during the first quarter, according to its most recent filing with the SEC. The fund owned 9,714 shares of the biopharmaceutical company’s stock after selling 36,956 shares during the period. UBS Group AG’s holdings in Ultragenyx Pharmaceutical were worth $658,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently modified their holdings of RARE. Fortaleza Asset Management Inc. increased its position in shares of Ultragenyx Pharmaceutical by 148.5% in the first quarter. Fortaleza Asset Management Inc. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $111,000 after buying an additional 980 shares in the last quarter. Pacer Advisors Inc. increased its position in shares of Ultragenyx Pharmaceutical by 22.6% in the first quarter. Pacer Advisors Inc. now owns 3,037 shares of the biopharmaceutical company’s stock valued at $206,000 after buying an additional 560 shares in the last quarter. Strs Ohio increased its position in shares of Ultragenyx Pharmaceutical by 10.7% in the first quarter. Strs Ohio now owns 3,100 shares of the biopharmaceutical company’s stock valued at $210,000 after buying an additional 300 shares in the last quarter. Ameritas Investment Partners Inc. increased its position in shares of Ultragenyx Pharmaceutical by 3.7% in the first quarter. Ameritas Investment Partners Inc. now owns 3,226 shares of the biopharmaceutical company’s stock valued at $219,000 after buying an additional 115 shares in the last quarter. Finally, Massmutual Trust Co. FSB ADV bought a new position in shares of Ultragenyx Pharmaceutical during the first quarter valued at approximately $237,000. Institutional investors and hedge funds own 95.71% of the company’s stock.
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) traded down 2.48% during trading on Friday, reaching $56.51. The company’s stock had a trading volume of 263,345 shares. The stock’s market cap is $2.40 billion. The company has a 50 day moving average of $64.40 and a 200-day moving average of $66.83. Ultragenyx Pharmaceutical Inc. has a 12-month low of $51.67 and a 12-month high of $91.35.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported ($1.72) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.73) by $0.01. During the same period last year, the firm earned ($1.46) earnings per share. Analysts forecast that Ultragenyx Pharmaceutical Inc. will post ($7.24) EPS for the current year.
ILLEGAL ACTIVITY WARNING: This story was first reported by BNB Daily and is the property of of BNB Daily. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://www.baseball-news-blog.com/2017/08/19/ubs-group-ag-lowers-stake-in-ultragenyx-pharmaceutical-inc-rare-updated-updated-updated.html.
RARE has been the subject of several analyst reports. Jefferies Group LLC raised their target price on Ultragenyx Pharmaceutical from $66.00 to $68.00 and gave the stock a “hold” rating in a research note on Monday, May 8th. Zacks Investment Research downgraded Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Stifel Nicolaus reiterated a “buy” rating and set a $111.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Friday, June 30th. Canaccord Genuity reiterated a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Monday, May 8th. Finally, Cowen and Company reiterated an “outperform” rating on shares of Ultragenyx Pharmaceutical in a research report on Thursday, June 29th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating and eight have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $83.50.
In other news, VP Theodore Alan Huizenga sold 480 shares of the stock in a transaction on Friday, May 26th. The stock was sold at an average price of $57.46, for a total value of $27,580.80. Following the sale, the vice president now directly owns 9,366 shares in the company, valued at $538,170.36. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 9.20% of the stock is currently owned by company insiders.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.
Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.